Inovio Pharmaceuticals (NASDAQ:INO – Get Free Report) and Scholar Rock (NASDAQ:SRRK – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Institutional & Insider Ownership
26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk and Volatility
Inovio Pharmaceuticals has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Scholar Rock has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for Inovio Pharmaceuticals and Scholar Rock, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inovio Pharmaceuticals | 1 | 1 | 4 | 0 | 2.50 |
| Scholar Rock | 2 | 2 | 10 | 3 | 2.82 |
Inovio Pharmaceuticals currently has a consensus price target of $6.33, suggesting a potential upside of 259.85%. Scholar Rock has a consensus price target of $69.50, suggesting a potential upside of 44.40%. Given Inovio Pharmaceuticals’ higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Scholar Rock.
Profitability
This table compares Inovio Pharmaceuticals and Scholar Rock’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inovio Pharmaceuticals | N/A | -28,886.30% | -75.67% |
| Scholar Rock | N/A | -175.27% | -86.66% |
Valuation and Earnings
This table compares Inovio Pharmaceuticals and Scholar Rock”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inovio Pharmaceuticals | $60,000.00 | 3,231.95 | -$84.95 million | ($0.54) | -3.26 |
| Scholar Rock | $570,000.00 | 10,302.06 | -$377.94 million | ($3.36) | -14.32 |
Inovio Pharmaceuticals has higher earnings, but lower revenue than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Scholar Rock beats Inovio Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology company developing DNA medicines, including treatments intended to stimulate the body’s immune response to cancers and infectious diseases. Its research has focused on therapeutic and preventive applications, with candidates targeting conditions such as human papillomavirus (HPV)-related disease. The company’s technology uses synthetic DNA plasmids designed to prompt cells to produce targeted antigens. Inovio has also developed its CELLECTRA platform, which uses electroporation to help deliver DNA medicines into cells.
About Scholar Rock
Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-?) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
